Parkinson’s disease is a long-term brain condition that affects movement, balance, and daily life.
It happens when certain brain cells slowly stop working and die. These cells normally help control movement by producing a chemical called dopamine.
When dopamine levels drop, people may develop shaking, stiffness, and slow movement. Around the world, nearly 10 million people live with this condition, and there is still no cure.
For many years, treatments have focused on easing symptoms rather than stopping the disease itself. This is why scientists are working hard to find new ways to target the root causes of Parkinson’s disease. A new study published in Nature Medicine offers an early but exciting step in this direction.
Researchers have been studying a gene called LRRK2, which is known to increase the risk of Parkinson’s disease. Some people carry changes in this gene that make the disease more likely to develop.
Even in people without these changes, the LRRK2 protein may still play a role in the disease. Because of this, scientists believe that reducing the activity of this protein could help protect the brain.
The new study tested an experimental drug called BIIB094. This drug is designed to “turn down” or silence the LRRK2 gene. It uses a special method known as antisense therapy. This approach works by blocking the instructions that tell the body to make a certain protein. In this case, the drug aims to reduce the amount of LRRK2 protein in the brain.
The clinical trial involved 82 people with Parkinson’s disease. It was carried out in two parts. In the first part, 40 participants received a single dose of the drug or a placebo.
In the second part, 42 participants received four doses over several weeks. The drug was delivered directly into the fluid around the brain and spinal cord using a medical procedure called a lumbar puncture.
The main goal of this early trial was to test safety. The results showed that the drug was generally well tolerated. Some participants experienced side effects, but most were mild or moderate. Importantly, no serious problems linked to the drug were reported.
The study also showed that the drug worked as expected inside the body. Levels of the LRRK2 protein dropped by up to 59 percent in people who received the treatment. This shows that the drug was able to reach its target and change the biological process linked to the disease.
Interestingly, the reduction in the protein was seen in both people with and without the gene mutation. This suggests that the treatment might help a wider group of patients in the future.
However, it is important to understand that this study did not test whether the drug improves symptoms or slows the disease. It only showed that the treatment appears safe and can affect the target in the body. Larger and longer studies are needed to see if patients actually feel better or decline more slowly.
Overall, this research marks an important step forward. It shows that it is possible to safely target a key gene linked to Parkinson’s disease. This opens the door to future treatments that may go beyond symptom control and instead change how the disease develops.
In reviewing the study, the results are promising but still early. The sample size was small, and the trial was not designed to measure long-term benefits. While the drop in the LRRK2 protein is encouraging, it is not yet clear if this will lead to real improvements in patients’ lives. More research is needed to confirm the benefits and ensure long-term safety.
Even so, this study gives hope that new treatments may one day slow or even stop the progression of Parkinson’s disease, offering a better future for millions of people.
If you care about Parkinson’s disease, please read studies that Vitamin B may slow down cognitive decline, and Mediterranean diet could help lower risk of Parkinson’s.
For more information about brain health, please see recent studies that blueberry supplements may prevent cognitive decline, and results showing Plant-based diets could protect cognitive health from air pollution.
Source: Northwestern University.
